CLMN Accumulation and ItsRelationtoDiseases (G79789)

Target Name: CLMN

NCBI ID: G79789

CLMN

CLMN Accumulation and ItsRelationtoDiseases

CLMN, or Creatinine, is a protein that is expressed in high levels in the liver and kidneys. It is a waste product that is generated by muscle metabolism and is typically eliminated from the body through the kidneys. However, individuals with certain genetic mutations, Such as those with the Gantry syndrome (GSDHD) or congenital jaundice (Joel's syndrome), where the liver cannot process CLMN properly, causing it to accumulate in the body. This will cause CLMN to accumulate in the blood and urine and cause a series of symptoms, such as jaundice, hepatosplenomegaly, and abnormal kidney function.

The accumulation of CLMN in the liver and kidneys is due to its small molecular weight, which allows it to easily enter these two organs through the liver and kidney filtration membranes. However, because CLMN accumulates in various tissues of the body, including the brain, heart, spleen, and lymph nodes, its concentration in these tissues may be higher than in blood and urine.

The accumulation of CLMN is also related to a variety of diseases. For example, in liver disease, accumulation of CLMN can lead to liver cell damage and fibrosis, increasing the risk of cirrhosis and liver cancer. In kidney disease, accumulation of CLMN can lead to tubular damage and renal dysfunction, increasing the risk of kidney failure.

In addition, the accumulation of CLMN is also related to the efficacy of some drugs. For example, certain antihypertensive drugs and antidepressants may increase the concentration of CLMN in the body, causing adverse effects. Therefore, researchers have been exploring new drug therapies to reduce the accumulation of CLMN and improve their efficacy.

In order to reduce the accumulation of CLMN in the body, researchers have adopted many methods. For example, the use of diuretics can increase the clearance of CLMN in the urine. The accumulation of CLMN in the liver can be reduced with hepatoprotective agents, such as liver transplantation and dietary modification. Additionally, the researchers studied the interactions of CLMN and found

Protein Name: Calmin

The "CLMN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLMN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets